DOCSLIB.ORG

有限公司 Testosterones

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
有限公司 Testosterones ® 伊域化學藥業（香港）有限公司 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD Rm 1006, 10/F, Hewlett Centre, Tel: (852) 25412772 (4 lines) No. 52-54, Hoi Yuen Road, Fax: (852) 25423444 / 25420530 / 21912858 Kwun Tong, E-mail: [email protected] YICK -VIC 伊域 Kowloon, Hong Kong. Site: http://www.yickvic.com Testosterones Product Code CAS Product Name MIS-42658 1043-10-3 (8S,9S,10R,11S,13S,14S,17S)-11,17-DIHYDROXY-10,13,17-TRIMETHYL-2,6,7,8,9,11,12,14,15,16-DECAHYDRO-1H-CYCLOPENTA[A]PHENA NTHREN-3-ONE UNIE-13864 564-35-2 11-KETOTESTOSTERONE PH-1081U 17-ALPHA-HYDROXYTESTOSTERONE ACETATE MIS-39218 51154-09-7 17ALPHA-METHYLTESTOSTERONE 4,5-EPOXIDE PH-1121 72-63-9 17BETA-HYDROXY-17-METHYLANDROSTA-1,4-DIEN-3-ONE MIS-34565 5585-85-3 17BETA-HYDROXY-17-METHYLANDROSTA-4,6-DIEN-3-ONE PH-1081S 17BETA-HYDROXYANDROST-1-ENE-3-ONE TETRAHYDROPYRANYL ETHER PH-1081VA 1-TESTOSTERONE ETHYL CARBONATE PH-1081VB 1-TESTOSTERONE METHYL CARBONATE PH-1081VC 1-TESTOSTERONE PROPYL CARBONATE PH-1081HB 1-TESTOSTERONE UNDECANOATE UNIE-15172 2141-17-5 4-HYDROXYTESTOSTERONE UNIE-13597 62-99-7 6BETA-HYDROXYTESTOSTERONE SPI-4361 14531-84-1 6-DEHYDRO-19-NORTESTOSTERONE PH-1081PK 1057-07-4 ANDROSTANOLONE 17-BENZOATE Copyright © 2018 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Page 1 of 3 Product Code CAS Product Name PH-1133 1605-89-6 BOLASTERONE UNIE-8525 CHLORDEHYDROMETHYLTESTOSTERONE PH-1081JA 1093-58-9 CLOSTEBOL PH-1081JB 855-19-6 CLOSTEBOL ACETATE SPI-0027GA 481-30-1 EPITESTOSTERONE SPI-0027GB EPITESTOSTERONE ACETATE PH-1081K 434-03-7 ETHISTERONE PH-1136B 76-43-7 FLUOXYMESTERONE MIS-20029 65-04-3 METHYL-1-TESTOSTERONE PH-1081L 58-18-4 METHYLTESTOSTERONE PH-1124A 434-22-0 NANDROLONE PH-1124B 360-70-3 NANDROLONE DECANOATE PH-1081Q 514-61-4 NORMETHANDRONE UNIE-6802 2446-23-3 ORAL TURINABOL UNIE-17751 33765-68-3 OXENDOLONE PH-1081N 434-07-1 OXYMETHOLONE PH-1081PA 521-18-6 STANOLONE PH-1081A 58-22-0 TESTOSTERONE UNIE-4924 TESTOSTERONE 17ALPHA-CYPIONATE UNIE-9028 2088-71-3 TESTOSTERONE 17-BENZOATE PH-1081EA 1045-69-8 TESTOSTERONE ACETATE PH-1081B 58-20-8 TESTOSTERONE CYPIONATE PH-1081C 5721-91-5 TESTOSTERONE DECAONATE PH-1081EE 7768-48-1 TESTOSTERONE DICHLOROACETATE ® Copyright © 2018 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 2 of 3 Product Code CAS Product Name PH-1081D 315-37-7 TESTOSTERONE ENANTHATE PH-1081BC 15262-86-9 TESTOSTERONE ISOCAPROATE MIS-16511 991-20-8 TESTOSTERONE PALMITATE PH-1081EK 5704-03-0 TESTOSTERONE PHENYLACETATE PH-1081F 1255-49-8 TESTOSTERONE PHENYLPROPIONATE PH-1081G 57-85-2 TESTOSTERONE PROPIONATE PH-1081HA 5949-44-0 TESTOSTERONE UNDECANOATE UNIE-3907 3764-87-2 TRESTOLONE Thank you for your interest in our products. For any enquires, please contact us at [email protected] \ Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement. Buyers shall verify the patent status for their respective country. Products currently covered by valid Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1) in the US, and EC Directive 2001/82/EC, 2001/83/EC, and their amendments in EU. Similar laws and rules may apply in other countries. ® Copyright © 2018 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 3 of 3 .
Load more

Recommended publications
  • Revisão Sistemática Da Reposição Com Testosterona Em Homens Obesos Com Níveis Séricos Baixos De Testosterona
    Universidade Estadual Paulista “Júlio de Mesquita Filho” Faculdade de Medicina Amanda Sampaio Mangolim Revisão Sistemática da reposição com testosterona em homens obesos com níveis séricos baixos de testosterona Dissertação apresentada à Faculdade de Medicina, Universidade Estadual Paulista “Júlio de Mesquita Filho”, Câmpus de Botucatu, para obtenção do título de Mestre pelo programa de Mestrado Profissional em Pesquisa Clínica. Orientadora: Profa. Assistente Dra. Vania dos Santos Nunes Nogueira Botucatu 2019 Amanda Sampaio Mangolim Revisão Sistemática da reposição com testosterona em homens obesos com níveis séricos baixos de testosterona Dissertação apresentada à Faculdade de Medicina, Universidade Estadual Paulista “Júlio de Mesquita Filho”, Câmpus de Botucatu, para obtenção do título de Mestre pelo programa de Mestrado Profissional em Pesquisa Clínica. Orientadora: Profa. Assoc. Vania dos Santos Nunes Nogueira Botucatu 2019 Epígrafe “Os que se encantam com a prática sem a ciência são como os timoneiros que entram no navio sem timão nem bússola, nunca tendo certeza do seu destino.” Leonardo da Vinci Dedicatória Dedico este trabalho ao meu bem mais precioso: MINHA FAMÍLIA ! Aos meus pais, Joselita e Olidio , que sempre me motivaram a buscar conhecimento e a lutar em busca dos meus sonhos, me dando base, exemplo e sendo meu porto seguro, sempre prontos a me auxiliar em qualquer empreitada. À minha irmã, Camila , minha grande amiga, que colaborou muito nesse processo e me apoiou com palavras de incentivo, amor e carinho. Ao meu namorado, Romulo , que me apoiou, me ajudou e me deu suporte para concluir esse trabalho. Amo vocês! Agradecimentos Agradeço primeiramente a Deus , pela dádiva da vida. À Profa.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • Progesterone 7K77 49-3265/R3 B7K770 Read Highlighted Changes Revised April, 2010 Progesterone
    en system Progesterone 7K77 49-3265/R3 B7K770 Read Highlighted Changes Revised April, 2010 Progesterone Customer Service: Contact your local representative or find country specific contact information on www.abbottdiagnostics.com Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert. Key to symbols used List Number Calibrator (1,2) In Vitro Diagnostic Medical Control Low, Medium, High Device (L, M, H) Lot Number Reagent Lot Expiration Date Reaction Vessels Serial Number Sample Cups Septum Store at 2-8°C Replacement Caps Consult instructions for use Warning: May cause an allergic reaction Contains sodium azide. Contact Manufacturer with acids liberates very toxic gas. See REAGENTS section for a full explanation of symbols used in reagent component naming. 1 NAME REAGENTS ARCHITECT Progesterone Reagent Kit, 100 Tests INTENDED USE NOTE: Some kit sizes are not available in all countries or for use on all ARCHITECT i Systems. Please contact your local distributor. The ARCHITECT Progesterone assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of progesterone in ARCHITECT Progesterone Reagent Kit (7K77) human serum and plasma. • 1 or 4 Bottle(s) (6.6 mL) Anti-fluorescein (mouse, monoclonal) fluorescein progesterone complex coated Microparticles SUMMARY AND EXPLANATION OF TEST in TRIS buffer with protein (bovine and murine) and surfactant Progesterone is produced primarily by the corpus luteum of the ovary stabilizers. Concentration: 0.1% solids. Preservatives: sodium azide in normally menstruating women and to a lesser extent by the adrenal and ProClin. cortex.1 At approximately the 6th week of pregnancy, the placenta 2-5 • 1 or 4 Bottle(s) (17.0 mL) Anti-progesterone (sheep, becomes the major producer of progesterone.
    [Show full text]
  • University of Groningen Multi-Residue Analysis of Growth Promotors In
    University of Groningen Multi-residue analysis of growth promotors in food-producing animals Koole, Anneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1998 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Koole, A. (1998). Multi-residue analysis of growth promotors in food-producing animals. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 APPENDIX 1 OVERVIEW OF RELEVANT SUBSTANCES This appendix consists of two parts. First, substances that are relevant for the research presented in this thesis are given. For each substance CAS number (CAS), molecular weight (MW), bruto formula (formula) and if available UV maxima and alternative names are given. In addition, pKa values for the ß-agonists are listed, if they were available.
    [Show full text]
  • Mucoadhesive Drug Delivery Devices and Methods Of
    (19) TZZ___T (11) EP 1 691 746 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/00 (2006.01) A61K 9/00 (2006.01) 27.05.2015 Bulletin 2015/22 A61K 9/16 (2006.01) A61K 38/38 (2006.01) A61K 47/10 (2006.01) (21) Application number: 04813308.6 (86) International application number: (22) Date of filing: 08.12.2004 PCT/US2004/040975 (87) International publication number: WO 2005/055945 (23.06.2005 Gazette 2005/25) (54) MUCOADHESIVE DRUG DELIVERY DEVICES AND METHODS OF MAKING AND USING THEREOF MUKOADHÄSIVE ARZNEIMITTELABGABEVORRICHTUNGEN UND VERFAHREN ZU IHRER HERSTELLUNG UND VERWENDUNG DISPOSITIFS D’ADMINISTRATION DE MEDICAMENTS MUCOADHESIFS ET PROCEDES DE FABRICATION ET D’UTILISATION ASSOCIES (84) Designated Contracting States: • BERG, Eric, P. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Plymouth, MN 55447 (US) HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR (74) Representative: Robertson, James Alexander et al (30) Priority: 08.12.2003 US 527962 P Marks & Clerk LLP 90 Long Acre (43) Date of publication of application: London WC2E 9RA (GB) 23.08.2006 Bulletin 2006/34 (56) References cited: (73) Proprietor: Gel-Del Technologies, Inc. WO-A1-01/28524 WO-A1-99/32107 St. Paul, MN 55114 (US) WO-A1-02/058735 US-A- 5 385 606 US-A- 5 863 554 US-A1- 2002 141 945 (72) Inventors: US-A1- 2003 215 515 • MASTERS, David, B. Hastings, MN 55033 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Poisons List (Jersey) Order 1986
    POISONS LIST (JERSEY) ORDER 1986 Revised Edition 20.775.60 Showing the law as at 31 August 2004 This is a revised edition of the law Poisons List (Jersey) Order 1986 Arrangement POISONS LIST (JERSEY) ORDER 1986 Arrangement Article 1 Poisons List ..................................................................................................... 5 2 Citation ............................................................................................................ 5 SCHEDULE 6 THE POISONS LIST 6 PART 1 6 PART 2 50 PART 3 52 Supporting Documents ENDNOTES 53 Table of Legislation History......................................................................................... 53 Table of Renumbered Provisions ................................................................................. 53 Table of Endnote References ....................................................................................... 53 Revised Edition – 31 August 2004 Page - 3 20.775.60 Poisons List (Jersey) Order 1986 Article 1 POISONS LIST (JERSEY) ORDER 1986 THE HEALTH AND SOCIAL SERVICES COMMITTEE in pursuance of Article 8 of the Pharmacy and Poisons (Jersey) Law 1952,1 orders as follows – Commencement [see endnotes] 1 Poisons List The list of substances which are to be treated as poisons for the purposes of the Pharmacy and Poisons (Jersey) Law 1952,2 shall be as set out in the Schedule to this Order. 2 Citation This Order may be cited as the Poisons List (Jersey) Order 1986. Revised Edition – 31 August 2004 Page - 5 20.775.60 SCHEDULE Poisons List (Jersey) Order
    [Show full text]
  • Alltech® Drug Standards for the Forensic, Clinical & Pharmaceutical Industries OH
    Alltech® Drug Standards For the Forensic, Clinical & Pharmaceutical Industries OH H3C H H H3C H HO Catalog #505B Our Company Welcome to the Grace's Alltech® Drug Standards Catalog W. R. Grace has manufactured high-quality silica for over 150 years. Grace has been behind the scenes for the past 30 years supplying silica to the chromatography industry. Now we’re in the forefront moving beyond silica, developing and delivering innovative complementary products direct to the customer. Grace Davison Discovery Sciences was founded on Grace’s core strength as a premier manufacturer of differentiated media for SPE, Flash, HPLC, and Process chromatography. This core competency is further enhanced by bringing seven well-known global separations companies together, creating a powerful new single source for all your chromatography needs. A Full Portfolio of Chromatography Products to Support Drug Standards: • HPLC Columns • HPLC Accessories • Flash Products • TLC Products • GC Columns • GC Accessories • SPE and Filtration • Equipment • Syringes • Tubing • Vials For complete details, download the Chromatography Essentials catalog from the Grace web site or contact your customer service representative. Alltech - Part of the Grace Family of Products In 2004, Alltech Associates Inc. was acquired by Grace along with the Alltech® Drug Standards product line. Through investment in research and strategic acquisitions, Grace has expanded our product range and global reach while drawing upon the support of the Grace corporate infrastructure and more than 6000 employees globally to support scientific research and analysis worldwide. With key manufacturing sites in North and South America, Europe, and Asia, plus an extensive international sales and distribution network, separation scientists throughout the world can count on timely delivery and expert local technical service.
    [Show full text]
  • Georgia State Forensic Drugs
    Comprehensive Forensic FT-IR Collection Library Listing – 4,286 spectra This extensive library contains materials not only of forensic interest but also for general problem solving and identification of unknown substances in industry and academia. The wide range of items include drugs, clandestine lab chemicals, explosives, paints, fabrics, dyes, polymers, inorganic compounds, pigments, adhesives, and other common materials. The library consists of 4,286 spectra that were acquired from a wide range of laboratories involved in forensic investigations. The collection includes the following classes of compounds: • Drugs of abuse, scheduled materials • Pharmaceuticals, vitamins and excipients • Clandestine lab materials and intermediates • Solvents, organic chemicals and hazardous chemicals • Accelerants • Lubricants and natural oils • Explosives, pyrotechnics, primers, powders and boosters • Herbal and plant material and fibers • Automobile paint vehicles, pigments, primers and clear coats • Textiles, natural and man-made fibers, carpet materials • Paints, coatings, varnishes, oils • Dyes and stains • Polymers, monomers, copolymers, plasticizers and rubbers • Inorganics, pigments, minerals and clays • Tape, adhesives, sealants, glues, caulks and putties • Crystal test derivatives and intermediates • Household chemicals, cleaning agents, surfactants and pesticide All spectra were measured using micro or macro Diamond ATR, thin films on salt windows or KBr pellets at 4 cm-1 spectral resolution. Comprehensive Forensic FT-IR Collection Index
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Identification of Unknown Residues
    Project number: 871.639.01 BAS-code: WOT-02-438-III-036 Project title: Identification of unknown residues Project leader: R.J.B. Peters Report 2009.013 November 2009 Identification of Unknown Residues using bioassay directed fractionation, UPLC/TOFMS analysis and database searching R.J.B. Peters, J.C.W. Rijk, J.E. Oosterink, A.W.J.M. Nijrolder and M.W.F. Nielen Business Unit: Veterinary Drugs Group: Analytical Services & Development RIKILT - Institute of Food Safety Wageningen University and Research Centre Akkermaalsbos 2, 6708 WB Wageningen, The Netherlands P.O. Box 230, 6700 AE Wageningen, The Netherlands Tel +31 317 480 256 Fax +31 317 417 717 Internet www.rikilt.wur.nl Copyright 2009, RIKILT – Institute of Food Safety. The client is allowed to publish or distribute the full report to third parties. Without prior written permission from RIKILT – Institute of Food Safety it is not allowed to: a) publish parts of this report; b) use this report or title of this report in conducting legal procedures, for advertising, acquisition or other commercial purposes; c) use the name of RIKILT – Institute of Food Safety other than as author of this report. The research described in this report was funded by the Dutch Ministry of Agriculture, Nature and Food Quality (WOT-02-438-III-036) Distribution list: • Food and Consumer Product Safety Authority (VWA); J.A. van Rhijn • National Institute for Public Health and the Environment (RIVM); drs. M. Blokland, dr. L. van Ginkel, drs. S.S. Sterk This report from RIKILT - Institute of Food Safety has been produced with the utmost care.
    [Show full text]